The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

The growing use of AI has opened new avenues for healthcare marketers, revolutionising how they approach new initiatives.

It is believed around 1,700 people could be eligible for the treatment, while the NHS estimates around 50 people a year will ...

The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds ...

ReniCel’s positive clinical performance did not help Editas to find partners interested in the license, which together with Vertex/Crispr slow Casgevy ... will happen (see image below).

Casgevy - also known as exa-cel - earned its ... to live free from the fear of sickle cell crises hanging over them." Image: Funmi Dasaolu has been campaigning for the drug to be approved.

Image Source: Zacks Investment Research Estimates ... While CRISPR’s pipeline is still in early-stage development, we believe that with Casgevy’s approval, the company has now crossed its ...

The ligand is linked to a radioactive isotope molecule that can either be used to image the tumour ... editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the ...

NHS officials estimate that around 50 people a year will receive treatment now that it has been approved for use for certain patients with severe sickle cell disease. Here patients have reacted to the ...

On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza ...

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...